MONTREAL, Aug. 30 /PRNewswire-FirstCall/ - CryoCath Technologies Inc., the global leader in cryotherapy products to treat cardiovascular disease, today announced the addition of Jesse Penn to the Company’s Board of Directors.
“We are pleased to welcome Jesse to the CryoCath Board of Directors,” said Henri Vienneau, Chairman of the Board. “Jesse’s extensive experience in all facets of global high tech medical businesses make him a valuable addition to our Board as we move towards the U.S. commercial launch of Arctic Front.”
During his successful tenure with Johnson & Johnson, Mr. Penn served in many different senior executive roles. These included Vice President, Global Operations at various Johnson & Johnson businesses, including Cordis Corporation, Vice President Global Marketing at Ethicon, and President Cordis Cardiology. Previously, Mr. Penn served on the Board of Advisors for the Howard University Business School and he currently sits on the Board of Directors for DFB Pharmaceuticals, Inc. Mr. Penn received a Bachelor of Science degree in Electrical Engineering from Howard University and graduated from the Harvard University Program for Management Development.
About CryoCath
CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes “forward-looking statements” that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath’s annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management’s Discussion and Analysis section.
CryoCath Technologies Inc.
CONTACT: visit our website at www.cryocath.com, or contact: Michael Moore,Investor Relations, Phone: (416) 815-0700 ext. 241, Fax: (416) 815-0080,E-mail: mmoore@equicomgroup.com
